021-51111890
购物车（）
sales@molnova.cn
Orelabrutinib
CAS No. 1655504-04-3
Orelabrutinib ( ICP-022 )
产品货号. M22427 CAS No. 1655504-04-3
Orelabrutinib 是一种口服活性且不可逆的布鲁顿酪氨酸激酶 (BTK) 抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1511 | 有现货 |
|
| 10MG | ￥2518 | 有现货 |
|
| 25MG | ￥4073 | 有现货 |
|
| 50MG | ￥5747 | 有现货 |
|
| 100MG | ￥7425 | 有现货 |
|
| 200MG | ￥9810 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1444 | 有现货 |
|
生物学信息
-
产品名称Orelabrutinib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Orelabrutinib 是一种口服活性且不可逆的布鲁顿酪氨酸激酶 (BTK) 抑制剂。
-
产品描述Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). (In Vitro):With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.(In Vivo):Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
-
体外实验With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.
-
体内实验Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
-
同义词ICP-022
-
通路Tyrosine Kinase
-
靶点BTK
-
受体BTK
-
研究领域——
-
适应症——
化学信息
-
CAS Number1655504-04-3
-
分子量427.5
-
分子式C26H25N3O3
-
纯度>98% (HPLC)
-
溶解度DMSO:250 mg/mL (584.80 mM; Need ultrasonic)
-
SMILESNC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.
产品手册
关联产品
-
AVL-292
AVL-292 (Spebrutinib, CC-292) 是一种高选择性、共价 Btk 抑制剂，IC50 <1 nM；对 Yes、c-Src、Brk、Lyn 和 Fyn 的抑制作用也较弱，IC50 分别为 723 nM、1.729 uM、2.43 uM、4.4 uM 和 7.15 uM。
-
Acalabrutinib enanti...
Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors. Acarabitinib enantiomers can be used in the study of cancer, autoimmune diseases and chronic inflammation.
-
QL-47
一种有效的、选择性的、不可逆的 BTK 抑制剂，IC50 为 7 nM。
